Faced with soaring demand for leucovorin for use in children with autism, the American Academy of Paediatrics (AAP) has said ...

That is a sizeable increase on Pfizer's September offer of $47.50 upfront and $22.50 in CVRs, which combined to give a deal ...

Electra Therapeutics has garnered the funds it needs to complete a pivotal trial of its lead drug, angling to become the ...

Both sales figures came in well ahead of analyst expectations and will heap pressure on Lilly's main rival in the GLP-1 ...

ESMO 2025 showcased the breadth and urgency of breast cancer research, which remains one of the most diagnosed malignancies ...

Final draft guidance on NHS use of the drug marks a "significant shift" from NICE's 2021 decision on the drug as a first-line ...

As drug development becomes more complex, so do the demands for accurate, reproducible bioanalytical data to prove their ...

Along with Verona, MSD has been adding to its post-Keytruda prospects with a string of acquisitions and licensing deals in ...

Welcome back to Changing Faces, in our final round-up for August and September there are plenty of Board appointments to ...

Thermo Fisher Scientific has agreed to acquire Clario Holdings for nearly $8.9 billion, in a deal that would give it control ...

Kennedy suggested the requirement for CES is one reason why the US is lagging behind other parts of the world in the rollout ...

CSL's already depressed share price sank further on the news of the delay, which chairman Dr Brian McNamee said was related ...